| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1586/ECI.10.14 |
| P698 | PubMed publication ID | 20441430 |
| P2093 | author name string | Andrea A Zachary | |
| Mary S Leffell | |||
| P2860 | cites work | The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 |
| Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 | ||
| Proteasome inhibition reduces donor-specific antibody levels | Q33383491 | ||
| Using real data for a virtual crossmatch | Q33467644 | ||
| Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial | Q34373536 | ||
| A nonsimultaneous, extended, altruistic-donor chain | Q34961171 | ||
| The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection | Q36772871 | ||
| 14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation | Q36795985 | ||
| Defining unacceptable HLA antigens | Q37236970 | ||
| Detecting and monitoring human leukocyte antigen-specific antibodies | Q37240375 | ||
| The emerging issue of MICA antibodies: antibodies to MICA and other antigens of endothelial cells | Q37323152 | ||
| Clinical relevance of complement-fixing antibodies in cardiac transplantation | Q37449663 | ||
| ABO incompatible renal transplantation: a paradigm ready for broad implementation | Q37454277 | ||
| The role of the histocompatibility laboratory in desensitization for transplantation | Q37471328 | ||
| Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody | Q37575872 | ||
| Management of the highly sensitized patient | Q37580270 | ||
| Nebulous humors: defining alloantibodies in the 21st century | Q39986589 | ||
| Association of kidney transplant failure and antibodies against MICA. | Q40227396 | ||
| Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. | Q40769068 | ||
| A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation | Q42607322 | ||
| HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report | Q43984184 | ||
| Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. | Q44092564 | ||
| A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection | Q44197767 | ||
| Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection | Q44469234 | ||
| Rituximab as treatment for refractory kidney transplant rejection | Q44899030 | ||
| Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification | Q44919347 | ||
| Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution | Q45185527 | ||
| Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts | Q45287212 | ||
| Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction | Q45309367 | ||
| Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. | Q46029481 | ||
| Kidney transplantation in a recipient with anti-HLA antibody IgM positive | Q46056178 | ||
| Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation | Q46077973 | ||
| Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. | Q46155750 | ||
| Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production | Q46270888 | ||
| The development of a successful multiregional kidney paired donation program | Q46316827 | ||
| Successful three-way kidney paired donation with cross-country live donor allograft transport | Q46337166 | ||
| Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy | Q46350406 | ||
| Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 | ||
| Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action | Q46681755 | ||
| Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation | Q46873864 | ||
| Human leukocyte antigen antibodies and chronic rejection: from association to causation | Q47563762 | ||
| Expanding kidney paired donation through participation by compatible pairs | Q47573317 | ||
| Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation | Q47641892 | ||
| Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. | Q47705702 | ||
| HLA-specific B cells: II. Application to transplantation | Q47791727 | ||
| Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. | Q47989446 | ||
| Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients | Q47989452 | ||
| Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor | Q47990514 | ||
| Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin | Q50132009 | ||
| Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. | Q51736686 | ||
| Clinical relevance of anti-HLA antibodies detected by flow-cytometry bead-based assays--single-center experience. | Q51930565 | ||
| Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. | Q51959096 | ||
| A computer match program for paired and unconventional kidney exchanges. | Q51966631 | ||
| Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. | Q52668051 | ||
| Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. | Q53243295 | ||
| Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. | Q53388181 | ||
| Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. | Q55034268 | ||
| P433 | issue | 3 | |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 449-460 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Barriers to successful transplantation of the sensitized patient | |
| P478 | volume | 6 |
| Q92129061 | Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol |
| Q39015291 | Clinical and immunological relevance of antibodies in solid organ transplantation |
| Q44910302 | Comparative performance evaluation of a donor-specific bead-based crossmatch technique for the detection of donor-specific anti-HLA antibodies in heart transplantation |
| Q37820683 | Desensitization: achieving immune detente |
| Q34133012 | Detection of anti-HLA antibodies in maternal blood in the second trimester to identify patients at risk of antibody-mediated maternal anti-fetal rejection and spontaneous preterm delivery |
| Q51354461 | EpHLA software: a timesaving and accurate tool for improving identification of acceptable mismatches for clinical purposes. |
| Q46436844 | Intravenous human immunoglobulin treatment of serum from HLA-sensitized patients in kidney transplantation |
| Q37158659 | Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies |
Search more.